Grete Roede og Navamedic lanserer nytt vektreduksjonskonsept: Lettere steg

Grete Roede and Navamedic have entered a commercial partnership to launch 'Lettere steg', a 12-week structured weight‑loss program that integrates Navamedic’s Modifast meal‑replacement products with Grete Roede’s nationwide network of certified advisors and digital channels; the program is due to launch in romjulen 2025 with further development through 2026. The deal leverages Grete Roede’s brand and customer reach alongside Navamedic’s consumer health and clinical nutrition portfolio to address rising obesity trends in Norway, creating a targeted consumer-health revenue opportunity for Navamedic, although no financial terms or guidance were disclosed.

Analysis

Market structure: direct winners are Navamedic (Nordic-listed; branded Modifast sales) and pharmacy/distribution partners plus Grete Roede’s advisory network; losers are pure‑digital, low‑touch weight‑loss apps and standalone meal‑replacement brands without clinical/channel reach. Expect modest pricing power — program is value‑added (service + product) so Navamedic can convert lower‑margin product sales into recurring guided‑service revenue; a realistic sales bump is +5–15% unit growth in Q1 2026 if national rollout gains traction.

Risk assessment: tail risks include regulatory pushback on claims or labeling, adverse safety/consumer reports, or Roede network underperformance; these would cause steep, near‑term revisions. Immediate market effect is negligible (days); monitor enrollment and retail sell‑through over 4–12 weeks post‑launch; if program doesn’t hit thresholds (see decisions) treat position as failed and cut losses. Hidden dependencies: success depends on Roede’s coach capacity, pharmacy shelf space, and Navamedic supply continuity.

Trade implications: tactical long exposure to Navamedic (see ticker recommendation) and selective overweight in consumer‑health/OTC distributors captures upside; use option spreads to cap downside around launch volatility. Pair trades: long Navamedic vs short pure‑play digital diet apps/brands that lack clinic distribution. Time entries around 2–4 weeks before launch and reassess after first enrollment metrics (end‑Jan 2026).

Contrarian angles: consensus understates potential margin compression from discounting to drive enrollments and overstates stickiness — many diet programs spike then revert. Historical parallels (OTC programs 2010–2015) saw front‑loaded demand then 30–50% drop in month‑6 retention; plan for a small, monitored position and avoid extrapolating launch momentum into long‑term wins without retention data.

Key Decisions for Investors

• Establish a 1–2% long position in Navamedic (Nordic listing; use NAVAMEDIC.OL if available) starting 2–4 weeks before the Lettere steg launch (mid‑Dec 2025), target +15–25% upside into Q1 2026 if Modifast sell‑through rises >10% vs prior quarter; cut to zero if enrollment <5,000 nationwide by end‑Jan 2026 or if sell‑through uplift <5%.
• Buy a limited cost‑defined bullish call spread on NAVAMEDIC.OL with strikes ~ATM and +15% out, expiry Mar 2026, sizing to equal 0.5–1% portfolio risk to capture launch upside while capping downside from negative headlines.
• Initiate a pair trade: long 1% portfolio in ORK.OL (Orkla, consumer/distribution exposure) and short 0.5% in WW (WW.US) to express preference for brick‑and‑mortar + OTC distribution over pure‑digital programs; reweight after retention data at 3 months (Apr 2026).
• Overweight Health Care/OTC exposure via XLV (2% overweight) and underweight Consumer Discretionary related to leisure/wellness apps by 1% through Q1 2026; rotate out if regulatory notices or advertisement restrictions appear within 60 days of launch.